Results · Apr-Jun 2026
Strides Pharma Science Q1 FY27 results
Sales grew 13% to ₹1,265 crore from ₹1,120 crore in Apr-Jun 2025.
Operating profit grew 5% to ₹230 crore, an operating margin of 18.2% (down 1.3 points from a year ago).
Net profit grew 57% to ₹165 crore from ₹106 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −4%, net profit +28%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 1,265 | 1,120 | +13% |
| Operating profit (EBITDA) | 229.8 | 218.1 | +5% |
| Operating margin | 18.2% | 19.5% | −1.3 pts |
| Net profit | 165.5 | 105.6 | +57% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.